Compare GTY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | ZLAB |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1998 | 2017 |
| Metric | GTY | ZLAB |
|---|---|---|
| Price | $36.09 | $20.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $32.60 | ★ $49.60 |
| AVG Volume (30 Days) | 533.0K | ★ 851.8K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | 8.00 | ★ 38.46 |
| EPS | ★ 0.43 | N/A |
| Revenue | $221,727,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $9.39 | $9.75 |
| Revenue Next Year | $7.83 | $26.03 |
| P/E Ratio | $83.93 | ★ N/A |
| Revenue Growth | 9.02 | ★ 15.33 |
| 52 Week Low | $25.39 | $15.96 |
| 52 Week High | $36.12 | $41.20 |
| Indicator | GTY | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 73.33 | 58.40 |
| Support Level | $32.41 | $16.84 |
| Resistance Level | N/A | $21.12 |
| Average True Range (ATR) | 0.58 | 0.82 |
| MACD | 0.18 | 0.16 |
| Stochastic Oscillator | 87.54 | 76.19 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.